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Abstract
Background: The role of pulmonary hypertension as a cause of mortality in sickle cell disease (SCD) is controversial.
Methods and Results: We evaluated the relationship between an elevated estimated pulmonary artery systolic pressure and
mortality in patients with SCD. We followed patients from the walk-PHaSST screening cohort for a median of 29 months. A
tricuspid regurgitation velocity (TRV)$3.0 m/s cuttof, which has a 67–75% positive predictive value for mean pulmonary artery
pressure $25 mm Hg was used. Among 572 subjects, 11.2% had TRV$3.0 m/sec. Among 582 with a measured NT-proBNP,
24.1% had values $160 pg/mL. Of 22 deaths during follow-up, 50% had a TRV$3.0 m/sec. At 24 months the cumulative
survival was 83%with TRV$3.0 m/sec and 98%with TRV,3.0 m/sec (p,0.0001). The hazard ratios for death were 11.1 (95% CI
4.1–30.1; p,0.0001) for TRV$3.0 m/sec, 4.6 (1.8–11.3; p = 0.001) for NT-proBNP$160 pg/mL, and 14.9 (5.5–39.9; p,0.0001) for
both TRV$3.0 m/sec and NT-proBNP$160 pg/mL. Age .47 years, male gender, chronic transfusions, WHO class III–IV,
increased hemolytic markers, ferritin and creatinine were also associated with increased risk of death.
Conclusions: A TRV$3.0 m/sec occurs in approximately 10% of individuals and has the highest risk for death of any
measured variable.
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Introduction
As patients with sickle cell disease age, repetitive cycles of end-
organ ischemia-reperfusion injury caused by vaso-occlusive events
and intravascular hemolysis and anemia lead to end organ injury
and failure [1,2]. The development of pulmonary vascular disease
and renal failure are particularly ominous. A series of studies using
Doppler-echocardiography to estimate pulmonary artery systolic
pressure has suggested that even mild elevations in estimated
pulmonary pressures are associated with a significant increase in
the risk of death [3–5]. Three clinical cohort studies have been
recently published defining pulmonary hypertension (PH) by the
gold standard, right heart catheterization [6–8]. These studies
reported a prevalence of PH of 6–10.5% and in all cases the
patients with PH exhibited an increased risk for early death.
Despite the consistent findings of these echocardiographic cohort
studies, and more recent right heart catheterization studies, the
importance of PH as both a common complication observed in the
adult sickle cell population and an attributable risk factor for death
has been questioned in editorial forums [9,10].
In the current study we estimate the prevalence of Doppler-
echocardiography defined PH and the impact on survival in the
largest screening cohort of patients with sickle cell disease, the
Treatment of Pulmonary Hypertension and Sickle Cell Disease
Table 1. Characteristics of Patients in Screening Cohort.
Total Median(IQR)1
Demographics, Genotype, and Vital Status
Age,years 632 37 (26–47)
Male, N(%) 632 294 (46.5)
SS Genotype, N(%) 632 466 (73.7)
Deaths, N(%) 632 22 (3.5)
Follow-up time, months 632 29.0 (25.1–33.4)
Clinical and Echocardiographic Measures
Hydroxyurea, current use, N(%) 632 238 (37.7)
Chronic Transfusions, N(%) 627 76 (12.1)
O2 Sat, % 625 97 (95–99)
Systolic Blood Pressure, mm Hg 628 118 (109–129)
Diastolic Blood Pressure, mm Hg 628 69 (62–75)
Six Minute Walk Distance, m 618 436 (378–500)
TRV, m/sec 572 2.5 (2.3–2.7)
Laboratory Measures
BNP, pg/mL 582 67.9 (29.0–155.0)
Ferritin, ng/mL 576 228.8 (93.2–520.8)
Fetal Hemoglobin, % 566 4.8 (1.5–10.6)
Hemolytic Component, relative unit 546 0.09 (21.20–1.29)
Absolute Reticulocyte Count,6106/mL 594 217.6 (139.0–320.1)
Reticulocytes, % 587 7.7 (4.2–11.8)
Hemoglobin, g/dL 615 9.2 (8.0–10.7)
Hematocrit, % 616 26.8 (22.9–31.0)
MCHC, g/dL 612 34.6 (33.6–35.7)
MCV, mm3 614 89.2 (81.6–98.1)
Platelets,6103/mL 614 341 (262–430)
RBC,6106/mL 615 2.95 (2.41–3.67)
WBC,6103/mL 615 9.2 (7.0–11.9)
Albumin, g/dL 615 4.2 (3.9–4.4)
Alkaline Phosphatase, U/L 615 86 (67–118)
ALT, U/L 619 22 (16–32)
AST, U/L 604 39 (27–54)
BUN, mg/dL 616 10.0 (7.0–28.0)
Creatinine, mg/dL 620 0.7 (0.6–0.9)
LDH, IU/L 584 367 (250–555)
Total Bilirubin, mg/dL 618 2.3 (1.4–3.6)
1Unless otherwise indicated.
doi:10.1371/journal.pone.0099489.t001
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with Sildenafil Therapy (walk-PHaSST) study [11,12]. This was
designed both as a screening study to assemble a large cohort of
patients with sickle cell disease and as an intervention trial to
examine the effects of sildenafil therapy on PH. In addition to
identifying the PH subjects eligible for the Main Intervention Trial
(MIT), the screening study collected extensive data on demo-
graphic, medical history, physical examination, laboratory, and
echocardiographic characteristics, and resulted in a large, multi-
center cohort of over 600 patients with sickle cell disease. An
observational follow-up study of screening study participants was
also implemented as part of the original protocol, during which
data on clinical outcomes, including deaths, were collected
prospectively during a follow-up period of approximately two
years. In this report, we present the results from this observational
follow-up and an examination of mortality in the walk-PHaSST
screening cohort and its association with various patient charac-
teristics.
For our analysis of prevalence and hazards ratios for death we
chose a conservative value for the tricuspid regurgitation velocity
of $3.0 m/sec. This value had a 67% positive predictive value for
PH measured by right heart catheterization (defined by a mean
pulmonary artery pressure of $25 mm Hg) in the French
screening study published by Parent and colleagues [6], and had
a 77% positive predictive value for PH in the NIH-pulmonary
hypertension screening study [8]. This TRV value provides a
more conservative population estimate of Doppler-defined PH
prevalence and impact on mortality than a cut-off value of 2.5 m/
sec. We recognize that the gold-standard for PH diagnosis is a
right heart catheterization, but this was not considered feasible for
the large number of patients enrolled in this NIH funded trial.
Methods
Study Design and Selection of Subjects
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.The study population and design have been described
in detail elsewhere [11,12]. In brief, we analyzed all members of
the screening cohort for whom follow-up data were available.
Local institutional review boards or ethics committees (University
of Pittsburgh, Columbia University, National Heart & Lung
Institute, Imperial College London, Howard University, Univer-
sity of Colorado, Denver, University of Illinois Chicago, Johns
Hopkins University, National Heart Lung and Blood Institute/
Figure 2. Prevalence of TRV, BNP, Six Minute Walk Distance,
and Fetal Hemoglobin. The screening study patient population
consisted of 671 patients with sickle cell anemia, 632 of whom were
followed for mortality over a median of 29 months. Ten percent (n = 64)
had TRV measurements of 3.0 m/sec or higher and 80% (n= 508) had
measurements less than 3.0 m/sec. TRV measurements were not
available for 10% (n= 60) of the patient population (diagonal stripes).
Twenty-two percent of patients (n = 140) had BNP measurements of
160 pg/mL or higher. Fourteen percent (n = 85) had six minute walk
distances less than 332 meters, and 46% (n = 289) had fetal hemoglobin
levels less than 5%.
doi:10.1371/journal.pone.0099489.g002
Figure 1. Study Flowchart.
doi:10.1371/journal.pone.0099489.g001
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NIH) approved the protocol and written informed consent was
obtained (ClinicalTrials.gov identifier NCT00492531). Written
informed consent was obtained from patients or their guardians in
the case of minors. Overall, we recruited 720 subjects age 12 and
over at steady state from nine different study sites in the United
States and one site in the United Kingdom. Of these, 632 (94.2%)
were followed for mortality and were included in our analysis; over
a median of 29 months, we observed 22 deaths. Deaths were
reported by study site coordinators and verified by review of
medical records, contact with next-of-kin, and/or death certifi-
cates when available.
Table 2. Cox Proportional Hazards Regression Analysis of Mortality for Demographic, Clinical, and Laboratory Characteristics.
Characteristic Category Total Deaths
Hazard Ratio (95%
CI)1 p
Age, years ----- 632 22 2.02 (1.1–3.8) 0.032
Gender F 338 7 1.0
M 294 15 2.48 (1.0–6.1) 0.048
Genotype SS 446 17 1.0
SC 166 5 0.83 (0.3–2.2) 0.71
Hydroxyurea use none/past 394 11 1.0
current 238 11 1.64 (0.7–3.8) 0.25
Chronic Transfusions no 551 15 1.0
yes 76 6 3.00 (1.2–7.7) 0.023
Moderate/Severe Pain episodes in past year 0–2 209 7 1.0
.2 420 14 1.02 (0.4–2.5) 0.96
Systolic BP, mm Hg ---- 628 21 1.62 (0.93–2.8) 0.086
TRV, m/sec ,3.0 508 10 1.0
3.0+ 64 11 9.55 (4.1–22.5) ,0.001
BNP, pg/mL2 --- 582 19 2.56 (1.8–3.6) ,0.001
BNP, pg/mL ,160 442 8 1.0
$160 140 11 4.55 (1.8–11.3) 0.001
Hemolytic Component, relative unit ,1.28 412 9 1.0
$1.28 134 10 3.43 (1.4–8.4) 0.007
Lactate dehydrogenase, IU/L3 ---- 584 19 1.68 (1.1–2.6) 0.021
Aspartate aminotransferase, IU/L3 ---- 604 21 1.91 (1.3–2.7) ,0.001
Reticulocytes, %2 ---- 585 20 1.07 (0.6–2.0) 0.83
Total bilirubin, mg/dL2 ---- 618 21 1.15 (0.7–2.0) 0.63
Six-Minute Walk, m $332 533 19 1.0
,332 85 3 1.01 (0.3–3.4) 0.99
NYHA/WHO Class I 439 11 1.0
II 141 7 1.96 (0.8–5.1) 0.17
III,IV 35 4 4.52 (1.4–14.3) 0.010
Hemoglobin, g/dL ---- 615 21 0.72 (0.4–1.4) 0.31
White blood cell count,6103/mL2 ---- 615 21 1.55 (0.8–2.9) 0.175
Absolute neutrophil count2 ---- 605 21 1.34 (0.8–2.3) 0.28
Platelets,6103/mL2 ---- 614 21 0.65 (0.4–1.0) 0.050
Hemoglobin F, %2 ---- 537 16 0.72 (0.3–1.5) 0.39
BUN, mg/dL2 ---- 616 20 1.24 (0.7–2.3) 0.49
Creatinine, mg/dL2 ---- 620 21 1.74 (1.4–2.2) ,0.001
Albumin, g/dL ---- 615 20 0.60 (0.4–0.8) 0.002
Alkaline phosphatase, U/L2 ---- 615 21 1.88 (1.2–3.0) 0.009
Alanine aminotransferase, U/L2 ---- 619 21 1.68 (1.1–2.6) 0.023
Ferritin, ng/mL2 ---- 576 21 2.58 (1.5–4.4) ,0.001
1Hazard ratios presented for 75th relative to the 25th percentile, unless otherwise indicated. All results are unadjusted.
2Transformed using the log or square root function.
3Adjusted for site-specific differences in normal ranges.
doi:10.1371/journal.pone.0099489.t002
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Evaluation of Subjects
All screening study subjects were evaluated by histories of
clinical events and lifetime treatments, physical examination,
laboratory screening, transthoracic Doppler echocardiography,
and the six-minute walk test. Routine laboratory tests (complete
blood count, serum chemistry profile, and lactate dehydrogenase)
from samples taken at the subject’s screening visit were performed
in the local laboratories of the participating institutions. Echocar-
diography was performed at the participating institutions and read
centrally in the NHLBI echocardiography core laboratory.
Percentage of hemoglobin F was measured by high-performance
liquid chromatography (HPLC) (Ultra Resolution System, Trinity
Biotech). Alpha-thalassemia was detected by molecular method-
ology based on polymerase chain reaction at the University of
Pittsburgh. Serum N-terminal pro-brain natriuretic peptide (NT-
pro BNP) concentration was measured by a sandwich immuno-
assay using polyclonal antibodies that recognize epitopes located in
the N-terminal segment (1–76) of pro-BNP (1–108) (Elecsys
analyser; Roche Diagnostics, Mannheim, Germany), as previously
described [13]. Ferritin was measured with an enzyme immuno-
assay (Ramco Laboratories Inc, Stafford, TX; reference range,
20–300 ng/mL).
Figure 3. Kaplan-Meier Analysis of Survival Time by TRV and BNP. Longer survival times were observed for a) subjects with TRV less than
3.0 m/sec (p,0.0001) and b) for subjects with BNP levels less than 160 pg/mL (p = 0.0003).
doi:10.1371/journal.pone.0099489.g003
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Statistical Analysis
Patient characteristics are presented as median and interquartile
range (IQR) or number and percentage of participants with a
given characteristic. TRV was categorized into two groups, $
3.0 m/sec and below 3.0 m/sec, based on now established high
PPV of this cut-off for PH defined by right heart catheterization;
NT-proBNP was categorized into two groups based on a cut-off
value of 160 pg/mL. A hemolytic component variable was derived
using principal component analysis from four markers of hemolysis
(lactate dehydrogenase, aspartate aminotransferase, total bilirubin,
and reticulocyte percent), as described elsewhere [14], and divided
into two groups based on the 75th percentile. Composite variables
combining correlated risk factors were derived to minimize the
effects on risk estimates of entering collinear variables simulta-
neously into statistical models. Associations of patient character-
istics with mortality were assessed using Cox proportional hazards
regression analysis, Kaplan-Meier survival curves, and the log-
rank test for differences across groups. Continuous variables were
log-transformed as necessary to normalize skewed distributions.
Patients were censored at the point of their last contact with study
staff if they did not have an event. Time to event or censoring was
measured from the date of entry into the screening study.
Regression coefficients were tested for significant differences from
zero by the Wald test. The proportional hazards assumption was
evaluated by testing the significance of each variable entered into
the model as a time dependent covariate. For the final model,
variables were entered in a stepwise approach if they had a
significant univariate association with mortality. All statistical
analyses were performed using PROC MEANS in SAS, version
9.1 (SAS Institute, Inc., Cary, NC) and STCOX and STS
GRAPH in Stata, version 11.1 (Statacorp, LP, College Station,
TX).
Results
Characteristics of the walk-PHaSST Screening Cohort
Demographic, clinical, laboratory, and echocardiographic
characteristics of the screening cohort are shown in Table 1
and Figure 1. Of the 632 participants, 47% were male and 74%
were homozygous for the hemoglobin S mutation. Study
participants ranged in age from 12 to 84 years, and the median
age was 37 years. A total of 22 deaths were observed during a
median follow-up time of 29 months.
The prevalence of characteristics that are generally thought to
be markers of poor relative health in patients with sickle cell
disease is shown in Figure 2. Sixty-four patients (10.1%) had
TRV measurements of 3.0 m/sec or higher, and140 (22.2%) had
NT proBNP measurements at least as high as 160 pg/mL, a
previously validated cut-off value associated with both PH and
mortality in patients with sickle cell disease [15,16]. Thirty-nine
(6.2%) patients had both TRV$3.0 m/sec and NT-proBNP$
160 pg/mL. Walk distances of less than 332 meters were observed
in 85 (13.5%) patients, and fetal hemoglobin levels less than 5%
were observed in 289 (45.7%) patients.
Table 3. Multivariate Cox Proportional Hazards Regression Analysis of Mortality.
Risk Factor Category N at Risk (deaths) Hazard Ratio (95% CI)1 p
TRV, m/sec ,3.0 445 (10) 1.0
3.0+ 57 (10) 4.12 (1.4–11.8) 0.008
Ferritin, ng/mL --- 502 (20) 1.80 (1.0–3.1) 0.038
Aspartate aminotransferase, U/L --- 502 (20) 1.85 (1.0–3.5 0.062
Creatinine, mg/dL and BNP, pg/mL2 0 339 (8) 1.0
(# of risk factors) 1 104 (2) 0.53 (0.1–2.5) 0.43
2 59 (10) 2.73 (0.9–8.4) 0.079
1HR is presented for 75th relative to the 25th percentile, calculated as ecoefficient6(75th percentile–25th percentile), for each variable listed in the table, unless otherwise indicated.
Values shown are adjusted for all other variables in the model.
2HR is given for the combined influence of creatinine and BNP on mortality as defined by the creatinine levels .0.9 or BNP levels $160, or both, relative to creatinine #
0.9 and BNP,160.
doi:10.1371/journal.pone.0099489.t003
Table 4. Cox Proportional Hazards Regression Analysis of Mortality for Composite of TRV and BNP.
Risk Factor Category N at Risk (deaths) Hazard Ratio (95% CI)1 p
Unadjusted TRV/BNP Composite1 0 381 (7) 1.0
(# of risk factors) 1 105 (3) 1.56 (0.4–6.0) 0.52
2 39 (9) 14.86 (5.5–39.9) ,0.001
Adjusted TRV/BNP Composite1,2 0 366 (7) 1.0
(# of risk factors) 1 96 (3) 1.44 (0.4–5.6) 0.60
2 36 (9) 11.10 (4.0–30.8) ,0.001
Ferritin, ng/mL3 --- 2.15 (1.2–3.8) 0.008
1HR is given for the combined influence of TRV and BNP on mortality as defined by TRV levels $3.0 or BNP levels $160, or both, relative to TRV,3.0 and BNP,160.
2Adjusted for ferritin.
3HR presented for 75th relative to the 25th percentile, calculated as ecoefficient6(75th percentile–25th percentile), and adjusted for TRV/BNP composite.
doi:10.1371/journal.pone.0099489.t004
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Univariate Associations with Mortality
Patient characteristics and their associations with mortality were
analyzed with Cox proportional hazards regression analysis
(Table 2). In this study, an increased risk of death was observed
for both age and gender, with males at two and a half times the
risk of dying relative to females (p = 0.05), and patients older than
47 years at twice the risk of dying compared with patients less than
26 years (p = 0.03). Associations with mortality were also observed
for chronic transfusions (p = 0.02) and a NYHA/WHO class value
or III or IV (p = 0.01). Variables not associated with mortality
included current hydroxyurea use, SC genotype, self-reported
history of painful episodes, and six-minute walk distance.
We also observed associations with mortality for two separate
biomarkers of pulmonary hypertension, TRV and NT-proBNP,
both of which were identified as risk factors for death in other
cohorts [3–5,13]. At 24 months the cumulative survival was 83%
for patients with TRV measurements of 3.0 m/sec or greater and
98% for patients below 3.0 m/sec (p,0.0001; Figure 3a).
Similarly, the cumulative survival was lower for patients with
NT-proBNP levels of 160 pg/mL or higher compared with levels
less than 160 pg/mL, although the magnitude of the difference
was not as large (92% for NT-proBNP$160 vs. 98% for NT-
proBNP,160, log-rank p= 0.0003; Figure 3b). The unadjusted
hazard ratios for death were 11.14 (95% CI 4.1–30.1; p,0.0001)
for patients with TRV$3.0 m/sec relative to TRV,2.7 m/sec
and 4.55 (95% CI 1.8–11.3; p = 0.001) for patients with NT-
proBNP$160 pg/mL relative to NT-proBNP levels , 160
(Table 2). For log-transformed NT-proBNP, the risk ratio for
death was 2.56 (95% CI 1.8–3.6; p,0.0001) for NT-proBNP
levels in the 75th percentile relative to NT-proBNP levels in the
25th percentile (Table 2).
Other variables associated with mortality in our cohort included
the calculated hemolytic component and two of the variables from
which it was calculated, aspartate aminotransferase (AST) and
lactate dehydrogenase, as well as ferritin and creatinine. Patients
with a hemolytic component value at least as large as 1.28, the 75th
percentile in this dataset, were at more than three times the risk of
dying relative to those patients with smaller values (HR=3.43,
95% CI 1.4–8.4; p= 0.007) (Table 2).
Multivariate Associations with Mortality
In stepwise multiple proportional hazards regression analysis,
the magnitude of the association between TRV and mortality was
decreased but still significant after adjustment for ferritin, AST,
creatinine and NT-proBNP (HR 4.27, 95%CI 1.3–14.1; p = 0.04;
Table 3). Comparing the 75th with the 25th percentiles of log-
transformed values, ferritin (HR 1.80, 95% CI 1.0–3.1; p= 0.04)
was also associated with mortality after adjustment for all other
variables in the model. AST was associated with mortality in the
multivariate model at the a=0.10 level (HR 1.84; 95%CI 0.95–
3.5; p = 0.07), as were creatinine and NT-proBNP, which were
entered into the model as a composite variables due to their high
pairwise correlation (Pearson r = 0.48, p,0.0001). Patients who
had both a high creatinine and a high NT-proBNP were at almost
3 times the risk of dying compared with patients with lower levels
(HR 2.71, 95% CI 0.9–6.2; p = 0.08).
The results from an analysis of TRV as a composite variable
combined with NT-proBNP are presented in Table 4. For
patients with both high TRV ($3.0 m/sec) and high NT-proBNP
($160 pg/mL), the unadjusted hazard ratio was 14.86 (95% CI
5.5–39.9; p,0.0001) and 11.10 (95% CI 4.0–30.8; p,0.0001)
after adjustment for ferritin. Adjustment for AST and creatinine
had little effect on the significance of the association between the
combined TRV and NT-proBNP variable and mortality and were
not included in the model.
Discussion
Here we show that amongst a large multinational cohort of
patients with SCD, a TRV$3.0 m/sec is common and has the
highest risk for death of any measured variable. This risk is higher
when an elevated TRV is combined with an elevated NT-proBNP
level confirming the value of these measurements as risk
stratification screening tools in patients with SCD.
An estimate based on a Doppler-echocardiographic measured
TRV value $3.0 m/sec suggests that 11.2% of the SCD
population screened are at high risk of having PH. This result is
consistent with the recently published analysis of the NIH-
Pulmonary Hypertension Screening Study, which reported 84
right heart catheterizations in 531 SCD subjects and a PH
prevalence of 10.4% [8]. It is also consistent with a PH prevalence
of 10% reported by Fonseca et al. in the evaluation of a smaller
Brazilian cohort [7]. These numbers are higher than the 6%
prevalence observed by Parent and colleagues, however they
excluded 10% of their patient population from screening, those
with elevated international normalized prothrombin time ratio .
1.7, estimated creatinine clearance ,30 mL per minute and
forced expiratory vital capacity ,70% predicted [6]. Because
hepatic dysfunction, renal insufficiency and low total lung capacity
are associated with PH in the sickle cell disease population [3,17],
they likely excluded a group with a much higher prevalence of PH.
This would be expected to reduce prevalence estimates.
This study identified a number of risk factors for early death
previously described in the Cooperative Study of Sickle Cell
Disease (CSSCD) such as age and male gender [18]. It also
confirmed risks associated with elevated TRV, elevated NT-
proBNP, increasing creatinine, intensity of hemolytic anemia, and
ferritin. Additionally, the New York Heart Functional Classifica-
tion and number of red blood cell units transfused were also found
to be associated with higher risk of death in univariate analysis. In
multivariate analysis TRV, ferrritin, AST, and creatinine or NT-
pro-BNP remained independent predictors of mortality. Of all the
measured parameters the TRV carried the highest hazards ratio
for early death, associated with a 10-fold increased risk. This was
even more significant when combined with a high NT-proBNP
(14-fold increased risk of death), potentially reflecting PH with
right heart failure.
There are a number of major limitations to this study. Most
patients with an elevated TRV did not have a right heart
catheterization to confirm the diagnosis of PH. For these estimates
we refer to the recent RHC studies and published operating
characteristics for this test at this threshold value. The causes of
death are largely unknown as there were no autopsies available
and the trial was not funded to establish the definitive cause of
death for all patients. In the recent analysis of the NIH-PH cohort,
death certificates were available for 15 out of 23 (65%) subjects
with PH and 80% of these subjects were reported to have had
right heart failure or sudden cardiac death stated as a cause of
death [8]. In addition, we cannot estimate the percentage of
patients with an elevated TRV that had pulmonary arterial
hypertension (PAH) or pulmonary venous (or post-capillary)
hypertension (PVH). According to the NIH cohort [8] study
5.8% of the entire cohort had PAH and in the Fonseca study
3.75% had PAH [7]; based on these data it is likely that half of the
patients with PH would have PAH and half PVH. It is notable in
the Mehari study that even patients diagnosed with PVH had
elevated transpulmonary gradients and the pulmonary vascular
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resistance and transpulmonary gradients predicted risk of death,
while the pulmonary capillary wedge pressure did not [8,19].
These data suggest that pulmonary vascular disease is central to
the mechanism of disease and death observed in the current study.
Recent editorials have suggested that PH is rare in patients with
sickle cell disease and not a cause of death ‘‘per se’’ in this patient
population [9,10]. To our knowledge, scleroderma, with a
prevalence of 7–11% and portopulmonary hypertension (1–6%
prevalence) are the only diseases with a prevalence of PAH that is
comparable to sickle cell disease. Based on this accepted high
prevalence, all patients with scleroderma and patients with portal
hypertension being evaluated for liver transplantation are screened
for the development of PH and referred to specialty care [20].
Similar to certain diseases associated with PAH, there have been
no completed trials in patients with sickle cell disease with
sufficient power to evaluate the efficacy of PAH targeted therapy.
However, there are a number of interventions that would be
expected to reduce morbidity and mortality in this population,
including more aggressive hydroxyurea or transfusion therapy,
iron chelation, supplemental oxygen and identification and
treatment of thromboembolic disease and sleep disordered
breathing. For these reasons, we suggest that screening for PH
associated with sickle cell disease is helpful and would have a
positive impact on the well-being of these patients.
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